Cases & Deals

  • Home
  • Practices
  • MedImmune licenses in IP on antibodies that target IL-5 receptor

Share

MedImmune licenses in IP on antibodies that target IL-5 receptor

December 2006

Clients MedImmune, Inc.

Jones Day represented MedImmune in an exclusive license to BioWa's POTELLIGENT technology platform and related intellectual property directed to antibodies that target the interleukin-5 (IL-5) receptor, including the transfer of Phase I clinical trials for treatment of asthma and other inflammatory diseases.

Contacts

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.